Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.semarthrit.2010.03.005
DC FieldValue
dc.titleDanazol in the Treatment of Systemic Lupus Erythematosus: A Qualitative Systematic Review
dc.contributor.authorLetchumanan, P.
dc.contributor.authorThumboo, J.
dc.date.accessioned2011-09-27T05:16:14Z
dc.date.available2011-09-27T05:16:14Z
dc.date.issued2011
dc.identifier.citationLetchumanan, P., Thumboo, J. (2011). Danazol in the Treatment of Systemic Lupus Erythematosus: A Qualitative Systematic Review. Seminars in Arthritis and Rheumatism 40 (4) : 298-306. ScholarBank@NUS Repository. https://doi.org/10.1016/j.semarthrit.2010.03.005
dc.identifier.issn00490172
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/26844
dc.description.abstractObjectives: To review and summarize published information on the use, effectiveness, and adverse effects of danazol in patients with systemic lupus erythematosus (SLE). Methods: A MEDLINE search from January 1950 to July 2009 was conducted using 2 search strategies retrieving 51 and 62 references, respectively. We also searched 2 standard reference textbooks and bibliographies of the 38 articles selected. Results: Of the 38 articles selected, there were 19 case series/reports with a total of 153 patients, including 2 prospective trials of 7 and 16 patients, respectively, and 1 randomized controlled trial of 40 patients. Danazol has been used successfully in the treatment of hematologic manifestations of SLE such as thrombocytopenia, Evan's syndrome, autoimmune hemolytic anemia, and a case of red cell aplasia. Thirteen patients responded to danazol after failing splenectomy. There is limited information on the use of danazol in nonhematologic manifestations of SLE. Adverse effects were generally tolerable but high doses may produce undesirable side effects for female patients. Conclusions: Danazol is a useful drug in the treatment of SLE patients, especially in patients with refractory thrombocytopenia, autoimmune hemolytic anemia, and premenstrual flares, and in some mild nonhematologic manifestations of SLE. It appears to be relatively well tolerated, safe, and efficacious. © 2010 Elsevier Inc. All rights reserved.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1016/j.semarthrit.2010.03.005
dc.sourceScopus
dc.subjectandrogens
dc.subjectautoimmune thrombocytopenia
dc.subjectdanazol
dc.subjectsystemic lupus erythematosus
dc.typeArticle
dc.contributor.departmentMEDICINE
dc.description.doi10.1016/j.semarthrit.2010.03.005
dc.description.sourcetitleSeminars in Arthritis and Rheumatism
dc.description.volume40
dc.description.issue4
dc.description.page298-306
dc.identifier.isiut000287014500003
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

15
checked on Oct 15, 2019

WEB OF SCIENCETM
Citations

13
checked on Oct 8, 2019

Page view(s)

292
checked on Oct 14, 2019

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.